Intuitive Surgical Stock Surges on Q4 Preliminary Revenue Beat

Core Viewpoint - Intuitive Surgical (ISRG) reported strong preliminary revenues for Q4 and full-year 2024, leading to a 7.7% increase in share price on January 15, 2025 [1] Q4 Preliminary Results - Worldwide revenues for Q4 2024 reached approximately $2.41 billion, reflecting a 25% year-over-year increase and surpassing Zacks Consensus Estimates of $2.21 billion [1] - Instruments and accessories revenues are expected to be around $1.41 billion, up 23% from the previous year [2] - Preliminary systems revenues are projected to be about $655 million, marking a 36% year-over-year growth [3] - The company placed 493 da Vinci Surgical systems in Q4 2024, an increase from 415 systems in the same period last year [4] Full-Year Preliminary Results - Full-year worldwide revenues are anticipated to be $8.35 billion, indicating a 17% year-over-year increase, exceeding the Zacks Consensus Estimate of $8.15 billion [5] - Instruments and accessories revenues for the full year are expected to be $5.08 billion, representing a 19% growth year-over-year [5] - Systems revenues improved by 17% to $1.97 billion compared to 2023 [5] Procedure Volume and Future Outlook - Procedure volumes have shown consistent growth, primarily driven by general surgery and cancer procedures, with an expected growth of approximately 13-16% in worldwide da Vinci procedures for 2025 [6] Price Performance - Intuitive Surgical's shares have increased by 22.5% over the past three months, outperforming the industry growth of 0.1% and the S&P 500's increase of 0.9% [8]